16% CHS ED Visit Spike After New ICD-10 Code: Hospital Burden Exposed

For emergency departments and hospital administrators, the CDC's report is a wake-up call: a single regulatory change—a new diagnosis code—caused a 16% leap in identified cases of a debilitating condition, immediately straining resources. The data show that CHS was always there, but now it is undeniably visible in claims and ED registries, forcing health systems to rethink triage protocols, staffing, and downstream care coordination.

The U.S. healthcare system is confronting a sharp rise in diagnosed cases of cannabis hyperemesis syndrome (CHS), a debilitating condition marked by recurrent nausea, vomiting, and severe abdominal pain, among frequent marijuana users. A new CDC report, covering emergency department data from approximately 7,500 facilities through May 2026, reveals a 16% spike in CHS-related ED visits following the implementation of a dedicated ICD-10 diagnostic code in October 2025. This increase, while partly artificial—reflecting improved case capture rather than a sudden surge in disease—unequivocally exposes a previously masked burden on hospitals and confirms that CHS is far more prevalent than prior estimates suggested.

“

For emergency departments and hospital administrators, the CDC's report is a wake-up call: a single regulatory change—a new diagnosis code—caused a 16% leap in identified cases of a debilitating condition, immediately straining resources.

For years, CHS was underdiagnosed because physicians lacked a specific billing code and often attributed symptoms to other gastrointestinal or behavioral causes. The CDC study found that from January 2023 through the summer of 2025, nearly 200,000 CHS-related visits occurred, yet the trend remained flat until the new code went into effect. The abrupt and sustained climb post-October underscores just how much underreporting distorted the true picture. The code’s introduction is a regulatory milestone that enables more accurate surveillance and may eventually drive reimbursement policies, clinical protocols, and resource allocation.

The demographic skew is striking. The largest increases were seen in ages 15–24, teenage girls, women, Black Americans, and American Indian and Alaska Natives. These disparities suggest not only differential patterns of use or biological susceptibility but also potential inequities in prior diagnosis. The data highlight that CHS is not an isolated curiosity but a growing public health concern affecting vulnerable populations, particularly as daily and high-potency cannabis use rises nationwide. With an estimated 2.75 million Americans already suffering annually, the syndromic burden on emergency rooms—where these patients often require extensive antiemetic therapy and intravenous fluids—is substantial and likely to intensify as awareness spreads.

Clinically, CHS is characterized by cycles of intractable vomiting that can lead to dehydration, kidney injury, and repeated hospitalizations. The only known cure is sustained cannabis cessation, but denial and dependence complicate treatment. For hospital systems, the operational implications are multifaceted: longer ED stays, increased admissions, and higher costs for a condition that many clinicians still misread as cyclic vomiting syndrome or food poisoning. The new code should accelerate education efforts and spur development of standardized treatment algorithms, yet gaps remain in outpatient management and access to substance use counseling.